CD177 Monoclonal Antibody (MEM-166 (MEM166)), eBioscience™, Invitrogen™

Description

• Description: The MEM-166 monoclonal antibody reacts with human CD177, a 58-64 kDa GPI-anchored glycoprotein
• The human CD177 locus codes for at least two alleles, NB1 and PRV-1, which differ by only 4 amino acids
• CD177 is expressed on granulocytes, early erythroblasts, megakaryocytes, promyelocytes and myelocytes
• CD177 mRNA levels are elevated in several different myeloproliferative disorders including polycythemia vera, and antibodies to CD177 are involved in neonatal alloimmune neutropenia, autoimmune drug inducedneutropenia, and graft failure following marrow transplantation
• Applications Reported: This MEM-166 (MEM166) antibody has been reported for use in flow cytometric analysis, immunoprecipitation, and immunoblotting (WB) (non-reducing conditions)
• Applications Tested: This MEM-166 (MEM166) antibody has been tested by flow cytometric analysis of normal human peripheral blood
• This can be used at less than or equal to 1 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Purity: Greater than 90%, as determined by SDS-PAGE
• Aggregation: Less than 10%, as determined by HPLC
• Filtration: 0.2 μm post-manufacturing filtered
• CD177 (NB1/HNA-2a and PRV-1 form) is a GPI-anchored glycoprotein present mainly on neutrophils
• Its plasma membrane expression is increased during pregnancy and and inflammation or after G-CSF application
• Ligand of CD177 has been identified as CD31 (PECAM-1)
• CD177 participates in neutrophil transmigration and seems to be also a pro-proliferative molecule
• The antibodies against CD177 can be involved in neonatal alloimmune neutropenia (NAN).